Appearing as a noteworthy advance in the fight against obesity, the drug is capturing considerable attention . It combines properties of two known GLP-1 binding agonists, semaglutide , and an additional glucose-dependent peptide component. Initial study data have shown significant body decrease in people with obesity , possibly presenting a effect